In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations. (October 2022) - Fischer, J.; Bouhana, K.; Chicarelli, M.J.; Dahlke, J.; Fell, B.; Fulton, J.; Guarnieri, A.; Haygood, L.; Jalluri, R.; Johnson, A.; McLean, B.; Max, M.; et al.